Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: March 12, 2024
The
breast
cancer
tumor
microenvironment
(TME)
is
dynamic,
with
various
immune
and
non-immune
cells
interacting
to
regulate
progression
anti-tumor
immunity.
It
now
evident
that
the
within
TME
significantly
contribute
resistance
conventional
newly
developed
therapies.
Both
in
play
critical
roles
onset,
uncontrolled
proliferation,
metastasis,
evasion,
Consequently,
molecular
cellular
components
of
have
emerged
as
promising
therapeutic
targets
for
developing
novel
treatments.
primarily
comprises
cells,
stromal
vasculature,
infiltrating
cells.
Currently,
numerous
clinical
trials
targeting
specific
are
underway.
However,
complexity
its
impact
on
evasion
immunity
necessitate
further
research
develop
improved
multifaceted
nature
arises
from
their
phenotypic
functional
plasticity,
which
endows
them
both
pro
during
progression.
In
this
review,
we
discuss
current
understanding
recent
advances
anti-tumoral
functions
implications
safe
effective
therapies
control
progress.
Journal of Translational Medicine,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: Oct. 2, 2023
Cancer
stem
cells
(CSCs)
have
emerged
as
key
contributors
to
tumor
initiation,
growth,
and
metastasis.
In
addition,
CSCs
play
a
significant
role
in
inducing
immune
evasion,
thereby
compromising
the
effectiveness
of
cancer
treatments.
The
reciprocal
communication
between
microenvironment
(TME)
is
observed,
with
TME
providing
supportive
niche
for
CSC
survival
self-renewal,
while
CSCs,
turn,
influence
polarization
persistence
TME,
promoting
an
immunosuppressive
state.
Consequently,
these
interactions
hinder
efficacy
current
therapies,
necessitating
exploration
novel
therapeutic
approaches
modulate
target
CSCs.
this
review,
we
highlight
intricate
strategies
employed
by
evade
surveillance
develop
resistance
therapies.
Furthermore,
examine
dynamic
interplay
shedding
light
on
how
interaction
impacts
progression.
Moreover,
provide
overview
advanced
that
specifically
which
hold
promise
future
clinical
translational
studies
treatment.
Cancer Discovery,
Journal Year:
2023,
Volume and Issue:
13(8), P. 1771 - 1788
Published: July 20, 2023
Abstract
Lineage
plasticity,
a
process
whereby
cells
change
their
phenotype
to
take
on
different
molecular
and/or
histologic
identity,
is
key
driver
of
cancer
progression
and
therapy
resistance.
Although
underlying
genetic
changes
within
the
tumor
can
enhance
lineage
it
predominantly
dynamic
controlled
by
transcriptional
epigenetic
dysregulation.
This
review
explores
regulators
plasticity
interplay
with
other
features
malignancy,
such
as
dysregulated
metabolism,
microenvironment,
immune
evasion.
We
also
discuss
strategies
for
detection
treatment
highly
plastic
tumors.
Significance:
hallmark
critical
facilitator
oncogenic
metastasis,
resistance,
It
essential
that
mechanisms
are
elucidated
enable
development
effectively
target
this
phenomenon.
In
review,
we
describe
cell
in
highlighting
therapeutic
approaches
may
be
harnessed
patient
benefit.
PLoS Biology,
Journal Year:
2024,
Volume and Issue:
22(2), P. e3002487 - e3002487
Published: Feb. 7, 2024
Epithelial-to-mesenchymal
transition
(EMT),
a
biological
phenomenon
of
cellular
plasticity
initially
reported
in
embryonic
development,
has
been
increasingly
recognized
for
its
importance
cancer
progression
and
metastasis.
Despite
tremendous
progress
being
made
the
past
2
decades
our
understanding
molecular
mechanism
functional
EMT
cancer,
there
are
several
mysteries
around
that
remain
unresolved.
In
this
Unsolved
Mystery,
we
focus
on
variety
types
metastasis,
cooperative
collective
behaviors,
spatiotemporal
characterization
EMT,
strategies
therapeutically
targeting
EMT.
We
also
highlight
new
technical
advances
will
facilitate
efforts
to
elucidate
unsolved
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: March 12, 2024
The
breast
cancer
tumor
microenvironment
(TME)
is
dynamic,
with
various
immune
and
non-immune
cells
interacting
to
regulate
progression
anti-tumor
immunity.
It
now
evident
that
the
within
TME
significantly
contribute
resistance
conventional
newly
developed
therapies.
Both
in
play
critical
roles
onset,
uncontrolled
proliferation,
metastasis,
evasion,
Consequently,
molecular
cellular
components
of
have
emerged
as
promising
therapeutic
targets
for
developing
novel
treatments.
primarily
comprises
cells,
stromal
vasculature,
infiltrating
cells.
Currently,
numerous
clinical
trials
targeting
specific
are
underway.
However,
complexity
its
impact
on
evasion
immunity
necessitate
further
research
develop
improved
multifaceted
nature
arises
from
their
phenotypic
functional
plasticity,
which
endows
them
both
pro
during
progression.
In
this
review,
we
discuss
current
understanding
recent
advances
anti-tumoral
functions
implications
safe
effective
therapies
control
progress.
